Overview

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
Children's Hospital & Research Center Oakland
UCSF Benioff Children's Hospital Oakland
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)
Treatments:
Acetylcarnitine
Antioxidants
Thioctic Acid